Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

13G Filing: Brookside Capital and Immune Design Corp. (IMDZ)

Page 1 of 7

Immune Design Corp. (NASDAQ:IMDZ): Bain Capital’s Brookside Capital filed an amended 13D.

You can check out Brookside Capital’s latest holdings and filings here.

Please follow Brookside Capital (if you aren’t already doing so) to get real-time email alerts whenever we publish an article about Brookside Capital or update its stock holdings.

Bain Capital
Bain Capital
Brookside Capital

You can access the original SEC filing by clicking here.

Ownership Summary Table

Name Sole Voting Power Shared Voting Power Sole Dispositive Power Shared Dispositive Power Aggregate Amount Owned Power Percent of Class
Bain Capital Public Equity Management 1,299,013 0 1,299,013 0 1,299,013 5.07%
Brookside Capital Investors II 1,299,013 0 1,299,013 0 1,299,013 5.07%
Brookside Capital Trading Fund 1,299,013 0 1,299,013 0 1,299,013 5.07%
Bain Capital
Bain Capital
Brookside Capital

Page 1 of 7 – SEC Filing

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
Under the Securities Exchange Act of 1934
(Amendment No. ________)*
Immune Design Corp. (Name of Issuer)
Common Stock
(Title of Class of Securities)
45252L103 (CUSIP Number)
September 29, 2017
(Date of Event which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant
to which this Schedule is filed:
? Rule 13d-1(b)
? Rule 13d-1(c)
? Rule 13d-1(d)
* The remainder of this cover page shall be filled out for a
reporting person’s initial filing on this form with respect
to the subject class of securities, and for any subsequent
amendment containing information which would alter disclosures
provided in a prior cover page.
The information required on the remainder of this cover page
shall not be deemed to be “filed” for the purpose of Section
18 of the Securities Exchange Act of 1934 (“Act”) or otherwise
subject to the liabilities of that section of the Act but shall
be subject to all other provisions of the Act (however, see the Notes).

CUSIP No. 45252L103

13G

Page 2 of 8

Follow Immune Design Corp. (NASDAQ:IMDZ)
Trade (NASDAQ:IMDZ) Now!
Page 1 of 7
Loading...